This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Frontotemporal Dementia Management Market

Market Insights onFrontotemporal Dementia Management covering sales outlook, demand forecast & up-to-date key trends

Frontotemporal Dementia Management Market by Drug Class Type, Distribution Channel, End-User & Region | Forecast 2023 to 2033

Frontotemporal Dementia Management Market Snapshot (2023 to 2033)

The global Frontotemporal Dementia Management Market is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Frontotemporal Dementia Management registered a CAGR of 4% in the historical period 2018 to 2022.

According to the World Health Organization, around 50 million people have dementia, and there are nearly 10 million new cases every year which is anticipated to boost the industry growth. Although the cause of Frontotemporal dementia is still unknown it majorly affects individuals between the ages of 40 to 60. Frontotemporal dementia causes serious psychotic episodes and language and communication problems not limited to patients only but affects people around them.

Report Attribute

Details

Expected Market Value (2023)

US$ 10 Million

Anticipated Forecast Value (2033)

US$ 17.91 Million

Projected Growth Rate (2023 to 2033)

6% CAGR

Customize this Report

Let us know your requirement to get
100% FREE customization

2018 to 2022 Frontotemporal Dementia Management Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Frontotemporal Dementia Management reflected a value of 4% during the historical period, 2018 to 2022.

A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering effective ways for Frontotemporal Dementia Management.

The market's growth is also attributed to the factors such as growing disease prevalence, a rise in lifestyle-associated concerns, and technological advancements. Furthermore, the increasing incidence of dementia patients, increasing research and development investments, and increasing drug development grants and funding by the government, as well as non-government organizations, are propelling immense growth.

In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights into key factors driving demand for Frontotemporal Dementia Management. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of dementia and others is fuelling the market growth. Thus, the market for Frontotemporal Dementia Management is expected to register a CAGR of 6% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Frontotemporal Dementia Management Market?

Increased Prevalence of the Condition to Push the Market Growth

The high prevalence of dementia is driving the growth of the market owing to treatment advancements and the development of novel therapies for dementia. Furthermore, the vulnerable aging population, government incentives, and benefits through special designation. According to the Centers for Disease Control and Prevention, by 2060, the number of Alzheimer’s disease cases is predicted to rise to an estimated 14 million people, with minority populations being affected the most.

Non-profit organizations and disease advocacy & private organizations currently are focusing on supporting drug development as the patient base of Frontotemporal dementia is expanding. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal dementia management.

These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop dementia. The population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Faced by the Frontotemporal Dementia Management Market?

Expensive Cost of Treatment to restrict Market Growth

The expensive treatment of Frontotemporal Dementia Management, less awareness of the condition, lack of proper diagnosis and higher chances of misunderstanding Alzheimer’s disease, and insubstantial and poor treatment options are hampering the market growth. Furthermore, lack of health remuneration policies, rise in cost, and side effects associated with certain treatments are expected to hinder the market growth.

Region-Wise Insights

How is the Market for Frontotemporal Dementia Management Market Turning Out in the Asia Pacific Region?

Improvement in healthcare spending propelling the growth of Frontotemporal Dementia Management in Asia Pacific

The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Frontotemporal Dementia Management Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the market worldwide.

China, with an attractive revenue contribution at present, is projected to remain a highly lucrative regional market for potential investors in the frontotemporal disorders treatment systems market.

The market in China is predicted to develop at the quickest rate due to increased disposable income. Moreover, the market growth is related to the increasing prevalence of frontotemporal disorders due to the growing elderly population base, as well as the poor immune system.

What are the Factors Boosting the Market for Frontotemporal Dementia Management in North America?

Technological Advancements Shaping Landscape for Frontotemporal Dementia Management in North America

North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. According to the Centers for Disease Control and Prevention, current estimates are that about 5.8 million people in the USA have Alzheimer’s disease and related dementias, including 5.6 million aged 65 and older and about 200,000 under age 65 with younger-onset Alzheimer’s.

Frontotemporal dementia falls under rare diseases or orphan indications. FTD affects around 30,000 to 40,000 patients in the U.S. Treatment of FTD falls under the auspices of the Orphan Drug Act of 1983 as orphan drug indications are those that affect less than 200,000 people in the U.S.A Orphan drug designation to FTD allows the continuation of clinical trial and orphan drug development with commercial incentives, prioritized consultation by FDA on clinical studies, and reduction in regulatory fees.

Government initiatives, an increase in the number of research partnerships, the presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool are boosting the market growth across North America.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-Wise Insights

By Drug Class Type, Which Segment is Likely to Account for a Prominent Share?

Antidepressants as an effective treatment to drive the market

A study conducted by the National Center for Biotechnology Information included ten studies with a total of 1592 patients. Eight included studies reported sufficiently detailed results to enter into analyses related to antidepressant efficacy. To analyze, the organization had nine groups of patients with dementia treated with antidepressants compared with nine groups receiving placebo treatment. As a result, participants on antidepressants were probably more likely to drop out of treatment than those on placebo over 6 to 13 weeks.

Considering this, FMI concludes that there are no specific treatments available to entirely stop the course of frontotemporal disorders. As a result, doctors may prescribe antidepressant medicines to help with anxiety and other symptoms.

By Distribution Channel, Which Segment is Likely to Account for a Significant Share?

Hospital Pharmacies to take the lead and drive market growth

According to the FMI analysis, Hospital pharmacies account for the largest market share. The requirement for several hospital stays and visits during Frontotemporal Dementia Management facilitates the growth of this segment. The majority of frontotemporal problems are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.

Start-ups Scenario

Key start-ups in the market include-

  • Geras Solutions aims to provide a clear pathway toward a reliable dementia specialist that is time and cost-effective. The Geras Solutions App offers individuals living with dementia and carers an ecosystem of digital dementia-supportive solutions via an easy-to-use mobile health tool.
  • Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical needs Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain, and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).

Market Competition

Key players in the Frontotemporal Dementia Management Market are Celgene Corporation, BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Sangamo Therapeutics, Orchard Therapeutics, CRISPR Therapeutics, and DisperSol Technologies among other global players.

  • In January 2021, LSP, the leading European life sciences investor, and Professor Philip Scheltens, a world-renowned dementia scientist, will launch the LSP Dementia Fund, a fund dedicated to fighting neurodegenerative diseases, in Amsterdam.
  • Alzheimer's Disease International, in collaboration with the Global Coalition on Aging (GCOA) and the Lien Foundation, will launch the third Dementia Innovation Readiness Index in 30 global cities around the world in October 2020.

Report Scope

Report Attribute

Details

Market Value in 2023

US$ 10 Million

Market Value in 2033

US$ 17.91 Million

Growth Rate

CAGR of 6% from 2023 to 2033

Base Year for Estimation

2022

Historical Data

2018 to 2022

Forecast Period

2023 to 2033

Quantitative Units

Revenue in USD Million and CAGR from 2023 to 2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis

Segments Covered

  • Drug Class Type
  • Distribution Channel
  • End-User
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Countries Profiled

  • United States of America
  • Canada
  • Brazil
  • Argentina
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • Association of Southeast Asian Nations
  • Gulf Cooperation Council
  • South Africa

Key Companies Profiled

  • Pfizer Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Mylan N.V.
  • Merck & Company, Inc.
  • AstraZeneca plc.
  • Allergen plc

Customization

Available Upon Request

Key Segments Profiled in the Frontotemporal Dementia Management Industry Survey

Drug Class Type:

  • Antidepressants
    • Fluoxetine
    • Fluvoxamine
    • Sertraline
    • Paroxetine
    • Citalopram
    • Bupropion
    • Mirtazapine
  • Antipsychotics
    • Olanzapine
    • Quetiapine
    • Ziprasidone
    • Aripiprazole
    • Risperidone
    • Paliperidone

End-Users:

  • Hospitals
  • Specialty clinics
  • Others

Distribution Channel:

  • Hospital Pharmacy
  • Drug store
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

From 2018 to 2022, the Frontotemporal Dementia Management Market grew at a CAGR of 4%.

The global Frontotemporal Dementia Management Market is expected to grow with a 6% CAGR during 2023 to 2033.

As of 2033, the Frontotemporal Dementia Management Market is expected to reach US$ 17.91 Million

According to the FMI analysis, hospital pharmacy account for the largest market share.

North America is expected to possess 25% market share for the Frontotemporal Dementia Management Market.

The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.

Table of Content

1. Executive Summary | Frontotemporal Dementia Management Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global analysis 2018 to 2022 and Forecast, 2023 to2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global analysis 2018 to 2022 and Forecast 2023 to2033, By Drug Class Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class Type, 2023 to2033

        5.3.1. Antidepressants

            5.3.1.1. Fluoxetine

            5.3.1.2. Fluvoxamine

            5.3.1.3. Sertraline

            5.3.1.4. Paroxetine

            5.3.1.5. Citalopram

            5.3.1.6. Bupropion

            5.3.1.7. Mitrazepine

        5.3.2. Antipsychotics

            5.3.2.1. Olanzapine

            5.3.2.2. Quetiapine

            5.3.2.3. Ziprasidone

            5.3.2.4. Aripiprazole

            5.3.2.5. Risperidone

            5.3.2.6. Paliperidone

    5.4. Y-o-Y Growth Trend Analysis By Drug Class Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class Type, 2023 to2033

6. Global analysis 2018 to 2022 and Forecast 2023 to2033, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to2033

        6.3.1. Hospital Pharmacy

        6.3.2. Retail Pharmacy

        6.3.3. Drug Store

        6.3.4. Online Pharmacy

        6.3.5. Others

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to2033

7. Global analysis 2018 to 2022 and Forecast 2023 to2033, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to2033

        7.3.1. Hospitals

        7.3.2. Specialty Clinics

        7.3.3. Others

    7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End User, 2023 to2033

8. Global analysis 2018 to 2022 and Forecast 2023 to2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. Middle East and Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America analysis 2018 to 2022 and Forecast 2023 to2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033

        9.2.1. By Country

            9.2.1.1. United States of America

            9.2.1.2. Canada

        9.2.2. By Drug Class Type

        9.2.3. By Distribution Channel

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class Type

        9.3.3. By Distribution Channel

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America analysis 2018 to 2022 and Forecast 2023 to2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class Type

        10.2.3. By Distribution Channel

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class Type

        10.3.3. By Distribution Channel

        10.3.4. By End User

    10.4. Key Takeaways

11. Europe analysis 2018 to 2022 and Forecast 2023 to2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Class Type

        11.2.3. By Distribution Channel

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class Type

        11.3.3. By Distribution Channel

        11.3.4. By End User

    11.4. Key Takeaways

12. Asia Pacific analysis 2018 to 2022 and Forecast 2023 to2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Drug Class Type

        12.2.3. By Distribution Channel

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class Type

        12.3.3. By Distribution Channel

        12.3.4. By End User

    12.4. Key Takeaways

13. MEA analysis 2018 to 2022 and Forecast 2023 to2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Drug Class Type

        13.2.3. By Distribution Channel

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class Type

        13.3.3. By Distribution Channel

        13.3.4. By End User

    13.4. Key Takeaways

14. Key Country's analysis

    14.1. United States of America

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Drug Class Type

            14.1.2.2. By Distribution Channel

            14.1.2.3. By End User

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Drug Class Type

            14.2.2.2. By Distribution Channel

            14.2.2.3. By End User

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Drug Class Type

            14.3.2.2. By Distribution Channel

            14.3.2.3. By End User

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Drug Class Type

            14.4.2.2. By Distribution Channel

            14.4.2.3. By End User

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Drug Class Type

            14.5.2.2. By Distribution Channel

            14.5.2.3. By End User

    14.6. United Kingdom

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Drug Class Type

            14.6.2.2. By Distribution Channel

            14.6.2.3. By End User

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Drug Class Type

            14.7.2.2. By Distribution Channel

            14.7.2.3. By End User

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Drug Class Type

            14.8.2.2. By Distribution Channel

            14.8.2.3. By End User

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Drug Class Type

            14.9.2.2. By Distribution Channel

            14.9.2.3. By End User

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Drug Class Type

            14.10.2.2. By Distribution Channel

            14.10.2.3. By End User

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Drug Class Type

            14.11.2.2. By Distribution Channel

            14.11.2.3. By End User

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Drug Class Type

            14.12.2.2. By Distribution Channel

            14.12.2.3. By End User

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Drug Class Type

            14.13.2.2. By Distribution Channel

            14.13.2.3. By End User

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Drug Class Type

            14.14.2.2. By Distribution Channel

            14.14.2.3. By End User

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Drug Class Type

            14.15.2.2. By Distribution Channel

            14.15.2.3. By End User

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Drug Class Type

            14.16.2.2. By Distribution Channel

            14.16.2.3. By End User

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Drug Class Type

            14.17.2.2. By Distribution Channel

            14.17.2.3. By End User

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Drug Class Type

            14.18.2.2. By Distribution Channel

            14.18.2.3. By End User

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Drug Class Type

            14.19.2.2. By Distribution Channel

            14.19.2.3. By End User

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Drug Class Type

            14.20.2.2. By Distribution Channel

            14.20.2.3. By End User

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Drug Class Type

        15.3.3. By Distribution Channel

        15.3.4. By End User

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Pfizer Inc.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Novartis AG

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. F. Hoffmann-La Roche Ltd.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. AstraZeneca GmbH

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Sanofi S.A

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Merck & Co., Inc.

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. TauRx Pharmaceuticals

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Alector Pharma Co.

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Bausch Health Companies Inc.

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. GlaxoSmithKline Plc.

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Value (US$ Million) Forecast by Drug Class Type, 2018 to 2033

Table 3: Global Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 4: Global Value (US$ Million) Forecast by End User, 2018 to 2033

Table 5: North America Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Value (US$ Million) Forecast by Drug Class Type, 2018 to 2033

Table 7: North America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 8: North America Value (US$ Million) Forecast by End User, 2018 to 2033

Table 9: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Value (US$ Million) Forecast by Drug Class Type, 2018 to 2033

Table 11: Latin America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 12: Latin America Value (US$ Million) Forecast by End User, 2018 to 2033

Table 13: Europe Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Value (US$ Million) Forecast by Drug Class Type, 2018 to 2033

Table 15: Europe Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 16: Europe Value (US$ Million) Forecast by End User, 2018 to 2033

Table 17: Asia Pacific Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: Asia Pacific Value (US$ Million) Forecast by Drug Class Type, 2018 to 2033

Table 19: Asia Pacific Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 20: Asia Pacific Value (US$ Million) Forecast by End User, 2018 to 2033

Table 21: MEA Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: MEA Value (US$ Million) Forecast by Drug Class Type, 2018 to 2033

Table 23: MEA Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 24: MEA Value (US$ Million) Forecast by End User, 2018 to 2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Value (US$ Million) by Drug Class Type, 2023 to2033

Figure 2: Global Value (US$ Million) by Distribution Channel, 2023 to2033

Figure 3: Global Value (US$ Million) by End User, 2023 to2033

Figure 4: Global Value (US$ Million) by Region, 2023 to2033

Figure 5: Global Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to2033

Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to2033

Figure 8: Global Value (US$ Million) Analysis by Drug Class Type, 2018 to 2033

Figure 9: Global Value Share (%) and BPS Analysis by Drug Class Type, 2023 to2033

Figure 10: Global Y-o-Y Growth (%) Projections by Drug Class Type, 2023 to2033

Figure 11: Global Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 12: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to2033

Figure 13: Global Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to2033

Figure 14: Global Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 15: Global Value Share (%) and BPS Analysis by End User, 2023 to2033

Figure 16: Global Y-o-Y Growth (%) Projections by End User, 2023 to2033

Figure 17: Global attractiveness by Drug Class Type, 2023 to2033

Figure 18: Global attractiveness by Distribution Channel, 2023 to2033

Figure 19: Global attractiveness by End User, 2023 to2033

Figure 20: Global attractiveness by Region, 2023 to2033

Figure 21: North America Value (US$ Million) by Drug Class Type, 2023 to2033

Figure 22: North America Value (US$ Million) by Distribution Channel, 2023 to2033

Figure 23: North America Value (US$ Million) by End User, 2023 to2033

Figure 24: North America Value (US$ Million) by Country, 2023 to2033

Figure 25: North America Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to2033

Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to2033

Figure 28: North America Value (US$ Million) Analysis by Drug Class Type, 2018 to 2033

Figure 29: North America Value Share (%) and BPS Analysis by Drug Class Type, 2023 to2033

Figure 30: North America Y-o-Y Growth (%) Projections by Drug Class Type, 2023 to2033

Figure 31: North America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 32: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to2033

Figure 33: North America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to2033

Figure 34: North America Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 35: North America Value Share (%) and BPS Analysis by End User, 2023 to2033

Figure 36: North America Y-o-Y Growth (%) Projections by End User, 2023 to2033

Figure 37: North American attractiveness by Drug Class Type, 2023 to2033

Figure 38: North American attractiveness by Distribution Channel, 2023 to2033

Figure 39: North America attractiveness by End User, 2023 to2033

Figure 40: North American attractiveness by Country, 2023 to2033

Figure 41: Latin America Value (US$ Million) by Drug Class Type, 2023 to2033

Figure 42: Latin America Value (US$ Million) by Distribution Channel, 2023 to2033

Figure 43: Latin America Value (US$ Million) by End User, 2023 to2033

Figure 44: Latin America Value (US$ Million) by Country, 2023 to2033

Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to2033

Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to2033

Figure 48: Latin America Value (US$ Million) Analysis by Drug Class Type, 2018 to 2033

Figure 49: Latin America Value Share (%) and BPS Analysis by Drug Class Type, 2023 to2033

Figure 50: Latin America Y-o-Y Growth (%) Projections by Drug Class Type, 2023 to2033

Figure 51: Latin America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 52: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to2033

Figure 53: Latin America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to2033

Figure 54: Latin America Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 55: Latin America Value Share (%) and BPS Analysis by End User, 2023 to2033

Figure 56: Latin America Y-o-Y Growth (%) Projections by End User, 2023 to2033

Figure 57: Latin America's attractiveness by Drug Class Type, 2023 to2033

Figure 58: Latin America attractiveness by Distribution Channel, 2023 to2033

Figure 59: Latin America attractiveness by End User, 2023 to2033

Figure 60: Latin America attractiveness by Country, 2023 to2033

Figure 61: Europe Value (US$ Million) by Drug Class Type, 2023 to2033

Figure 62: Europe Value (US$ Million) by Distribution Channel, 2023 to2033

Figure 63: Europe Value (US$ Million) by End User, 2023 to2033

Figure 64: Europe Value (US$ Million) by Country, 2023 to2033

Figure 65: Europe Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Value Share (%) and BPS Analysis by Country, 2023 to2033

Figure 67: Europe Y-o-Y Growth (%) Projections by Country, 2023 to2033

Figure 68: Europe Value (US$ Million) Analysis by Drug Class Type, 2018 to 2033

Figure 69: Europe Value Share (%) and BPS Analysis by Drug Class Type, 2023 to2033

Figure 70: Europe Y-o-Y Growth (%) Projections by Drug Class Type, 2023 to2033

Figure 71: Europe Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 72: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to2033

Figure 73: Europe Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to2033

Figure 74: Europe Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 75: Europe Value Share (%) and BPS Analysis by End User, 2023 to2033

Figure 76: Europe Y-o-Y Growth (%) Projections by End User, 2023 to2033

Figure 77: Europe attractiveness by Drug Class Type, 2023 to2033

Figure 78: Europe attractiveness by Distribution Channel, 2023 to2033

Figure 79: Europe attractiveness by End User, 2023 to2033

Figure 80: Europe attractiveness by Country, 2023 to2033

Figure 81: Asia Pacific Value (US$ Million) by Drug Class Type, 2023 to2033

Figure 82: Asia Pacific Value (US$ Million) by Distribution Channel, 2023 to2033

Figure 83: Asia Pacific Value (US$ Million) by End User, 2023 to2033

Figure 84: Asia Pacific Value (US$ Million) by Country, 2023 to2033

Figure 85: Asia Pacific Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: Asia Pacific Value Share (%) and BPS Analysis by Country, 2023 to2033

Figure 87: Asia Pacific Y-o-Y Growth (%) Projections by Country, 2023 to2033

Figure 88: Asia Pacific Value (US$ Million) Analysis by Drug Class Type, 2018 to 2033

Figure 89: Asia Pacific Value Share (%) and BPS Analysis by Drug Class Type, 2023 to2033

Figure 90: Asia Pacific Y-o-Y Growth (%) Projections by Drug Class Type, 2023 to2033

Figure 91: Asia Pacific Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 92: Asia Pacific Value Share (%) and BPS Analysis by Distribution Channel, 2023 to2033

Figure 93: Asia Pacific Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to2033

Figure 94: Asia Pacific Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 95: Asia Pacific Value Share (%) and BPS Analysis by End User, 2023 to2033

Figure 96: Asia Pacific Y-o-Y Growth (%) Projections by End User, 2023 to2033

Figure 97: Asia Pacific attractiveness by Drug Class Type, 2023 to2033

Figure 98: Asia Pacific attractiveness by Distribution Channel, 2023 to2033

Figure 99: Asia Pacific attractiveness by End User, 2023 to2033

Figure 100: Asia Pacific attractiveness by Country, 2023 to2033

Figure 101: MEA Value (US$ Million) by Drug Class Type, 2023 to2033

Figure 102: MEA Value (US$ Million) by Distribution Channel, 2023 to2033

Figure 103: MEA Value (US$ Million) by End User, 2023 to2033

Figure 104: MEA Value (US$ Million) by Country, 2023 to2033

Figure 105: MEA Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: MEA Value Share (%) and BPS Analysis by Country, 2023 to2033

Figure 107: MEA Y-o-Y Growth (%) Projections by Country, 2023 to2033

Figure 108: MEA Value (US$ Million) Analysis by Drug Class Type, 2018 to 2033

Figure 109: MEA Value Share (%) and BPS Analysis by Drug Class Type, 2023 to2033

Figure 110: MEA Y-o-Y Growth (%) Projections by Drug Class Type, 2023 to2033

Figure 111: MEA Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 112: MEA Value Share (%) and BPS Analysis by Distribution Channel, 2023 to2033

Figure 113: MEA Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to2033

Figure 114: MEA Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 115: MEA Value Share (%) and BPS Analysis by End User, 2023 to2033

Figure 116: MEA Y-o-Y Growth (%) Projections by End User, 2023 to2033

Figure 117: MEA attractiveness by Drug Class Type, 2023 to2033

Figure 118: MEA attractiveness by Distribution Channel, 2023 to2033

Figure 119: MEA attractiveness by End User, 2023 to2033

Figure 120: MEA attractiveness by Country, 2023 to2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Rheumatic-Heart Disease Management Market

Published : January 2023

Healthcare

Hirschsprung Disease Treatment Market

Published : September 2017

Healthcare

Autoimmune Disease Therapeutics Market

Published : February 2016

Healthcare

Infectious Disease Diagnostics Market

Published : January 2016

Google translate

Frontotemporal Dementia Management Market